Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Top Cited Papers
Open Access
- 29 November 2018
- Vol. 175 (7), 1731-1743.e13
- https://doi.org/10.1016/j.cell.2018.10.014
Abstract
No abstract availableKeywords
Funding Information
- European Research Council (694502)
- Agence Nationale de la Recherche
- Equipe Labellisée “La Ligue,”
- Ligue Nationale Contre le Cancer
- MSDAVENIR
- Innate Pharma
- CIML
- Marseille Immunopole
This publication has 55 references indexed in Scilit:
- Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunityJournal of Clinical Investigation, 2011
- Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung CarcinomaCancer Research, 2011
- Development and Function of CD94-Deficient Natural Killer CellsPLOS ONE, 2010
- Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cellsInnate Immunity, 2009
- Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapiesCancer, 2008
- Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based TherapyJournal of Clinical Oncology, 2007
- Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated CytolysisAnnual Review of Immunology, 2001
- NK cell recognition of non-classical HLA class I moleculesSeminars in Immunology, 2000
- Recognition of the Class Ib Molecule Qa-1b by Putative Activating Receptors Cd94/Nkg2c and Cd94/Nkg2e on Mouse Natural Killer CellsThe Journal of Experimental Medicine, 1999
- CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodiesEuropean Journal of Immunology, 1996